Perrigo Reports First Quarter 2021 Financial Results From Continuing Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Perrigo (PRGO) Misses Q1 EPS by 7c, Revenues Miss; Offers FY21 EPS Mid-Point Guidance Above Consensus
May 11, 2021 6:32 AM EDTPerrigo (NYSE: PRGO) reported Q1 EPS of $0.50, $0.07 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $1.02 billion.
President and CEO, Murray S. Kessler commented, "Two years ago, we began our journey to transform Perrigo from a healthcare to a consumer self-care company and with the actions taken this quarter, that transformation is now nearly complete. On March 1, 2021, we announced the divestment of our generic Rx business, our tenth transaction over the last two years, essentially completing our portfolio reconfiguration. We have made the necessary... More
